02.19.24 -- Partners To Support Your Biologic API & Drug Product Projects

Explore how an advanced CLD platform for new biologics can enable CHO-based cell line development, ensure premium, stable, and high-yield results, overcome common expression bottlenecks, and provide robust verification, genomic characterization, and monoclonality assessment services.

We are your life science solutions partner who ensures you have the right end-to-end solutions to address challenges in early development, commercialization, and post-market for combination products, biologics, and medical devices.

As recombinant protein and mAb treatments continue to provide promising pathways for both existing indications and new ones, Resilience has the clinical and commercial experience, expertise, and capacity to be your preferred manufacturing partner.

Enhanced by the most talented minds in physics, AI, biology, and engineering, our nanoparticle engineering, formulation, and GMP manufacturing services can drive forward your market success and unlock the power of “small."

PCI’s global manufacturing capabilities are in complex formulations, high potency, and lyophilization. Our capabilities cover a broad range of injectables including nanoparticles, mRNA, mAbs, proteins, oligonucleotides, and other biologics across multiple delivery formats. Explore end-to-end biologic solutions.

Over the years, we’ve learned invaluable lessons in the development of large molecule biologics and share our project management experience to support our customers’ drug strategies. Backed by Pfizer resources, we deliver technical expertise, global regulatory support, and long-term supply.

MilliporeSigma can help you reduce the time and cost to clinic with confidence and build on a scalable, purpose-built process that delivers success all the way through Phase 2 and meets regulatory requirements for IND filing.

Singota has built its business — processes, equipment, communications, and more — with a focus on meeting clients’ tight timeline requirements. We regularly help early-stage clinical clients (preclinical through Phase 3) progress from finalization of a project plan to filling a manufacturing batch within 8-12 weeks.

Achieving the correct heterodimerization of light and heavy chains during bispecific production can be challenging, and whilst the knobs-into-holes technology solves heavy chain mispairing, bYlok® offers a solution to address HC-LC mispairing.

Simtra is a premier CMO with a singular focus on sterile injectable drug product form/fill/finish services. Simtra can support both clinical and commercial scale projects and a variety of drug types, either cytotoxic or of standard potency, in a variety of platforms including liquid and lyophilized vials and pre-filled syringes.

Learn how a CDMO with expertise encompassing microbial fermentation, mechanical and chemical cell lysis, product recovery, and downstream purification can support your microbial biomanufacturing needs.

With cutting-edge facilities, tailored solutions, and a trusted track record, Samsung Biologics is continuously evolving to meet the needs of sponsors trying to advancing a complex therapeutic toward clinical trials and eventual commercialization.